A Trial of Low-dose Adjunctive alTeplase During prIMary PCI

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The purpose of this study is to determine the safety and efficacy of reduced doses (10 mg and 20 mg) of intra-coronary alteplase compared with placebo as an adjunct to PCI in reducing MVO and its consequences in high risk patients with STEMI.
Epistemonikos ID: a2db037e3d1966d8725a57d4e3e7818dadee4600
First added on: May 12, 2024